UroGen Pharma Earnings Call: Launch Momentum Meets Rising Costs

Urogen Pharma ((URGN)) has held its Q4 earnings call. Read on for the main highlights of the call.

UroGen Pharma’s latest earnings call struck an overall upbeat tone, with management emphasizing accelerating product momentum, strong clinical data, and improved financing as key pillars of the story. Still, investors were reminded that losses are widening and 2026 spending will climb, making the coming year a crucial test of execution and commercial durability.

Zasturi Launch Accelerates on Permanent J‑Code

Zasturi delivered $15.8 million in 2025 net product revenue, with a dramatic ramp from $1.8 million in the third quarter to $14 million in the fourth quarter as launch efforts took hold. Management said the permanent, product‑specific J‑code effective January 1, 2026 has already driven noticeable gains in prescriber activity, enrollments, and new patient starts.

Adoption Metrics Point to Broadening Market Penetration

By year‑end 2025, the company reported 838 activated sites of care, 102 unique prescribers, and 32 repeat prescribers for Zasturi, alongside payer coverage reaching more than 95% of covered lives. Early 2026 trends show use shifting toward the community setting, with roughly a 50‑50 split between hospitals and community practices, suggesting broader real‑world uptake.

Jelmyto Remains a Stable Revenue Pillar

Jelmyto generated $94 million in net product revenue in 2025, reaffirming its role as the company’s commercial backbone. For 2026, management guided Jelmyto sales to a range of $97 million to $101 million, implying modest but steady year‑over‑year growth of about 3% to 7%.

Company Revenue Growth Shows Early Payoff From Launch

Total company revenue climbed to $109.8 million in 2025 from $90.4 million in 2024, a roughly 21% increase driven primarily by the Zasturi launch and higher Jelmyto sales. This step‑up underscores how the expanding uro‑oncology portfolio is beginning to translate scientific progress into tangible top‑line growth.

UGN‑103 Phase 3 Data Underpin Next Wave of Growth

The company highlighted robust Phase 3 results for UGN‑103, its next‑generation Cysitore candidate, with a 77.8% complete response rate at three months in the Utopia trial, closely matching prior ENVISION data. Kaplan‑Meier estimates showing about 80% of patients disease‑free at 12 months and roughly 72% at 24 months support plans for a 2026 NDA filing and potential 2027 approval.

Broader Pipeline Builds Multiple Shots on Goal

Beyond UGN‑103, management expects to complete Phase 3 enrollment for UGN‑104 by 2026 and is advancing UGN‑501 into first‑in‑human studies with an IND filing targeted for 2026. The team also plans FDA Type C meetings and aims to expand UGN‑103 into additional settings, including high‑grade and adjuvant indications, potentially enlarging its addressable market.

Refinancing Extends Runway and Supports Strategy

UroGen entered a second amended senior secured term loan facility totaling $250 million, split into two tranches, to refinance its prior debt and add nondilutive capital. The initial $200 million was funded at closing, while a $50 million tranche remains available through mid‑2027, with a fixed 8.25% rate and principal payments not starting until 2030, giving management more flexibility to fund launches and trials.

Operational Feedback Highlights Real‑World Appeal of Zasturi

Management shared positive anecdotal feedback from physicians indicating Zasturi’s six‑dose outpatient regimen fits smoothly into routine workflows, which helps minimize disruption in practice operations. Patients reportedly value having a nonsurgical outpatient alternative, and early 2026 indicators have already surpassed the company’s internal benchmarks from Jelmyto’s launch.

Net Loss Widens as Investment Cycle Deepens

Despite revenue growth, the company’s net loss increased to $153.5 million in 2025 from $126.9 million in 2024, reflecting a heavier investment phase. Loss per share widened from $2.96 to $3.19, underscoring the gap UroGen must close between commercial momentum and the cost of scaling its portfolio.

High 2026 Operating Spend Reflects Launch and Pipeline Push

For 2026, UroGen guided operating expenses to a sizable $240 million to $250 million, including $20 million to $24 million of non‑cash share‑based compensation. Higher spending will be fueled by an expanded salesforce post‑Zasturi approval, elevated share‑based compensation, and life‑cycle management and development work for UGN‑103.

R&D Outlays Rise With Late‑Stage Programs

Research and development expenses climbed to $67.1 million in 2025 from $57.1 million in 2024, a roughly 17.5% increase tied to several late‑stage efforts. The company cited pre‑approval manufacturing for Zasturi, Phase 3 trial costs for UGN‑103 and UGN‑104, and acquisition‑related expenses for UGN‑501 as key drivers.

Financing Costs Shift Amid Evolving Capital Structure

Interest expense on the prior term loan rose to $15.3 million in 2025 from $12.5 million in 2024, partly due to an additional tranche drawn late in 2024, while other financing costs moved lower. Expense linked to a prepaid forward obligation decreased to $18.5 million from $23.4 million, reflecting a more favorable financing mix ahead of the new loan facility.

Lack of Zasturi Guidance Adds an Element of Uncertainty

Management declined to issue formal 2026 sales guidance for Zasturi, citing the product’s early stage of commercialization even as early indicators look strong. This leaves investors without a clear near‑term revenue target for the new therapy, adding uncertainty around how quickly Zasturi’s growth will translate into overall financial improvement.

Cash Position Demands Execution to Reach Sustainability

The company ended 2025 with $120.5 million in cash, cash equivalents, and marketable securities, supplemented by the new term loan facility that adds nondilutive capital. However, ongoing operating losses and an elevated 2026 spend plan mean that successful commercialization of Zasturi and advancement of the pipeline will be critical to strengthening the long‑term financial profile.

Guidance Highlights Modest Jelmyto Growth and Heavy Investment

For 2026, UroGen expects Jelmyto revenue between $97 million and $101 million, pointing to low‑single‑digit to mid‑single‑digit growth from 2025 levels, while operating expenses are projected at $240 million to $250 million, including non‑cash compensation. Management reiterated Zasturi’s peak sales potential of more than $1 billion and an anticipated roughly four‑year ramp but will revisit formal guidance only after more post‑J‑code visibility, supported by a year‑end cash balance of $120.5 million and access to the remaining term loan tranche.

UroGen’s call painted the picture of a company in the midst of a high‑investment, high‑opportunity phase, with strong launch metrics, compelling clinical data, and a bolstered balance sheet supporting its ambitions. For investors, the key question now is whether the early traction of Zasturi and the advancing pipeline can scale fast enough to offset rising costs and move the company toward a more sustainable financial footing.